| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MIF2; hcp-4; CENP-C; CENPC1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CENPC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CENPC抗体的3篇参考文献及其摘要概括：
1. **文献名称**: *Autoantibodies to centromere protein C (CENP-C) in systemic sclerosis: a retrospective study of progression complications*
**作者**: Sato S, et al.
**摘要**: 研究分析了CENPC抗体在系统性硬化症(硬皮病)患者中的临床意义，发现其与肺动脉高压和皮肤纤维化进展相关，是预后不良的潜在生物标志物。
2. **文献名称**: *Molecular characterization of CENPC-specific autoantibodies in limited cutaneous systemic sclerosis*
**作者**: Mahler M, et al.
**摘要**: 通过免疫印迹和ELISA技术验证CENPC抗体的特异性，揭示其与CREST综合征(钙质沉着、雷诺现象、食管功能障碍等)的高度相关性，并探讨其分子表位特征。
3. **文献名称**: *CENP-C antibodies in autoimmune diseases: clinical associations and diagnostic utility*
**作者**: Fritzler MJ, et al.
**摘要**: 多中心研究比较CENPC抗体与其他抗着丝粒抗体(如CENPB)的诊断差异，指出CENPC抗体对硬皮病亚型的特异性更高，且在部分原发性胆汁性胆管炎患者中也有检出。
注：以上为模拟文献摘要，实际文献需通过PubMed等数据库检索核实。
The CENPC antibody is an autoantibody targeting centromere protein C (CENP-C), a critical component of the centromere, a chromosomal region essential for proper chromosome segregation during cell division. CENP-C is part of the constitutive centromere-associated network (CCAN) and localizes to the inner kinetochore plate, where it interacts with other centromeric proteins (e.g., CENP-A, CENP-B) and DNA to maintain centromere integrity and mediate microtubule attachment.
CENPC antibodies are primarily associated with autoimmune conditions, particularly systemic sclerosis (scleroderma), where they are classified as a subset of antinuclear antibodies (ANA). They are also detected in other autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary biliary cholangitis (PBC). These antibodies were first identified in the 1980s alongside other anticentromere antibodies (ACA), which typically target CENP-A, CENP-B, and CENP-C.
Clinically, CENPC antibodies serve as diagnostic markers, especially for limited cutaneous systemic sclerosis (lcSSc) or CREST syndrome (Calcinosis, Raynaud’s phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia). Their presence correlates with specific disease phenotypes and may predict clinical progression. Detection methods include immunofluorescence assays (IFA) and ELISA. While their exact pathogenic role remains unclear, their formation is linked to genetic susceptibility, epigenetic dysregulation, and environmental triggers. Research continues to explore their mechanistic involvement in autoimmunity and potential as prognostic indicators.
×
